Market revenue in 2023 | USD 164.7 million |
Market revenue in 2030 | USD 232.9 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.93% in 2023. Horizon Databook has segmented the Latin America pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The Latin America pancreatic cancer diagnostics market has exhibited significant growth in the past few years due to the increase in the prevalence of pancreatic cancer in the region. Several surveys by various government and nonprofit organizations revealed that overall cancer mortality in Latin America is almost twice that of high-income countries.
These factors are expected to contribute to market growth during the forecast period. In the past few years, the region has witnessed rapid growth in cancer screening techniques, along with other cancer detection methods, due to increasing funding & implementation of various cancer programs.
However, poor infrastructure and inaccessibility to remote regions, low affordability, & shortage of skilled professionals may hamper market growth in this region during the forecast period. In August 2021, Dasa, the healthcare network in Brazil, expanded its partnership with SOPHiA GENETICS SA, which aims to introduce the inaugural decentralized cancer biomarker detection solution in Latin America.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America pancreatic cancer diagnostic market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account